Boiron (BOIRF) Stock Price, News & Analysis

Company Overview

Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary homeopathic medicines and homeopathic specialties; and other healthcare products include medical devices, invitro diagnostics, dietary supplements, cosmetics, and phytotherapy. It also provides homeopathic specialties comprising Oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; Camilia for the treatment of teething problems for babies; Sédatif PC to treat anxiety and emotional, and minor sleep disorders; Coryzalia for the treatment of cold symptoms and rhinitis; Homéoptic to treat eye discomfort and irritation due to various causes for adults and children; Homéovox for vocal disorders; Homéoplasmine for treating irritated skin and redness; Varésol to treat symptoms of chickenpox; and Arnicare Arthritis for use in the treatment of benign trauma pain. In addition, it offers Dermoplasmine, a plant based multi-use balm that repairs and protects irritated and damaged skin; COVID self-tests and rapid antigenic tests; LABIAMEO, that used to treat outbreaks of localized cold sores; and CONVAMEO to treat physical and mental asthenia. The company offers its products through distribution centers, pharmacies, pharmacy chains, wholesalers, grocery and drugstores, health food stores, and online retail. Boiron SA was founded in 1932 and is headquartered in Messimy, France.

Key Stats

• Today's Range: $35.85 to $35.85
• 50-Day Range: $35.85 to $35.85
• 52-Week Range: $32.90 to $53.50
• Volume: N/A
• Average Volume: 308 shs
• Market Capitalization: N/A
• P/E Ratio: 9.09
• Dividend Yield: 3.35%
• Price Target: N/A
• Consensus Rating: N/A

Boiron Stock Analysis - MarketRank™

Boiron scored higher than 14% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Boiron.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Boiron is 9.09, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 135.98.

Price to Earnings Ratio vs. Sector

The P/E ratio of Boiron is 9.09, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 143.06.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Boiron has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Boiron pays a meaningful dividend of 2.01%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Boiron does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Boiron is 30.44%. This payout ratio is at a healthy, sustainable level, below 75%.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Boiron has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

News Sentiment

Boiron has a news sentiment score of -0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Medical companies.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Boiron insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 9.72% of the stock of Boiron is held by institutions.

BOIRF Stock Analysis - Frequently Asked Questions

How have BOIRF shares performed this year?

Boiron's stock was trading at $42.54 at the beginning of the year. Since then, BOIRF shares have decreased by 15.7% and is now trading at $35.85.
View the best growth stocks for 2024 here.

How do I buy shares of Boiron?

Shares of BOIRF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:BOIRF
• CUSIP: N/A
• CIK: N/A
• Web: www.boiron.com
• Phone: 33 4 78 45 61 00
• Fax: N/A
• Employees: 2,501
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: 9.09
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A